Semaglutide versus liraglutide in efficacy and safety for managing type 2 diabetes mellitus complicated with obesity
Objective To compare semaglutide with liraglutide in therapeutic effectiveness and safety profile for manage-ment of type 2 diabetes mellitus in patients with obesity to explore the advantage of semaglutide in treatment of type 2 diabetes that is further complicated by obesity.Methods A total of 120 patients with type 2 diabetes and obesity admitted to Hai'an People's Hospital from August 2022 to December 2023 were enrolled in this study.These patients were divided into the liraglutide group(n=60,receiving treatment with liraglutide)and semaglutide group(n=60,receiving treatment with semaglutide)using a random number table method.The indicators including blood glucose-related indexes(fasting blood glucose,2-hour postprandial blood glucose,glycated hemoglobin),obesity-related indexes(waist circumference,body mass index)and adverse reactions that occurred during the treatment process before and after treatment were compared between the two groups.Results In the semaglutide group,the fasting blood glucose,2-hour postprandial blood glucose,and glycated hemoglobin levels were(7.28±0.59)mmol·L-1,(11.19±0.53)mmol·L-1,and(6.70±0.34)%,respectively,all of which were lower than those of(9.68±0.76)mmol·L-1,(13.65±0.62)mmol·L-1,and(7.72±0.44)%in the liraglutide group.The differences were statistically significant(t=19.322,23.362,14.209,all P＜0.05).The waist circumference and body mass index(BMI)in the semaglutide group were(23.00±0.95)kg·m-2 and(89.52±2.93)cm,respec-tively,which were both lower than those of(93.26±3.94)kg·m-2 and(25.23±1.05)cm in the liraglutide group.The observed differ-ences reached a level of statistical significance(t=5.900,12.199,both P＜0.05).The frequency of adverse reactions in the semaglutide treatment cohort was comparable to that observed in the liraglutide cohort,with an incidence rate of 3.33%for semaglutide and 5.00%for liraglutide,showing no statistically significant difference(χ2=0.209,P=0.648).Conclusion Semaglutide demonstrates a more significant therapeutic effect than liraglutide in the treatment of type 2 diabetes mellitus complicated with obesity.This medication is more effective in lowering blood glucose levels and improving obesity symptoms in patients,and it is associated with fewer adverse reactions as compared with liraglutide.
Type 2 diabetes mellitus complicated with obesitySemaglutideLiraglutideBlood glucose related indicatorObesity-related indicatorAdverse reaction
万方数据
维普
